Hester Biosciences Ltd - 524669 - Announcement Under Regulation 30 (LODR) - Corporate Presentation
Hester Biosciences released its Corporate Presentation for FY26. The presentation highlights strong financial growth with consolidated net profit increasing by 99% to Rs.57.48 crore and consolidated revenue rising by 7% to Rs.332.60 crore.
May 15 2026 17:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Hester Biosciences informed that the audio recording of its earnings conference call for the financial results of Q4 FY26 is now available on the company website for investor access.
May 15 2026 16:05:00
Hester Biosciences Ltd - 524669 - Disclosure On Board Approval For Re-Classification Request Under Regulation 31A Of SEBI Listing Regulations
Hester Biosciences board approved the request for re-classification of promoters Mr. Ravin Gandhi and Ms. Bela Gandhi to the 'public' shareholder category. This re-classification is contingent upon receiving a No Objection Certificate from the stock exchanges.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Intimation Of Receipt Of Requests For Reclassification From The 'Promoters' To The 'Public' Category In Accordance With Regulation 31A Of SEBI Listing Regulations
Hester Biosciences received requests from two promoters, Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake), for reclassification of their shareholdings from 'Promoter' to 'Public' category. This formalizes their passive investment status and lack of management involvement.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Change in Management
Hester Biosciences re-appointed Ms. Priya Gandhi as Executive Director for a three-year term, effective October 28, 2026. She is the daughter of CEO & MD Rajiv Gandhi and has been instrumental in driving the company's strategic direction.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Hester Biosciences reported strong Q4 FY26 consolidated results, with revenue growing 22% YoY and net profit soaring 974% YoY to INR 165.46 million. The board also recommended a dividend of INR 11 per equity share for FY26.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Board Meeting Outcome for Outcome Of Board Meeting Held On 15 May 2026
Hester Biosciences reported Q4 FY26 cons. revenue of ₹100.11 crores (up 22% YoY) and net profit of ₹16.55 crores (up 974% YoY). The board also recommended a ₹11 dividend per share for FY26 and divested 43.81% stake in subsidiary TLPL.
May 15 2026 11:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Hester Biosciences is scheduling an earnings conference call on May 15, 2026, at 2:00 PM IST. Management will discuss the financial performance for Q4 and the full fiscal year ended March 31, 2026, following the results announcement.
May 11 2026 16:05:00
Hester Biosciences Ltd - 524669 - Board Meeting Intimation for Financial Results And Dividend
Hester Biosciences' Board of Directors will hold a meeting on May 15, 2026. The agenda includes considering the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and the declaration of a dividend for the financial year 2025-26.
May 08 2026 16:05:00
Hester Biosciences Limited
Hester Biosciences' promoters and promoter group declared no direct or indirect encumbrance on their shareholding for the financial year ended March 31, 2026. This declaration was made by Mr. Rajiv Gandhi, a person acting in concert, and is a compliance filing.
Apr 23 2026 14:04:00
Read More